Deep Vein Thrombosis (DVT), Potential Market Opportunity & Clinical Pipeline Insights, 2019

Thrombosis is referred to a serious heart condition in which arteries or veins are blocked because of a blood clot in the blood vessel. Based on the location of the clot, it is classified as Venous and Arterial Thromboembolism. Deep vein thrombosis (DVT) is nothing but the forming blood clot in a vein deep in the body. Mostly the deep vein clots occur in the legs, which can cause pain and redness in the legs and swell in the lower leg, foot, and ankle. It is one of the parts of venous thromboembolism (VTE), in which the blood clots that are formed in the deep veins of the leg move to the lungs and blocks blood vessels. This leads to the presence of low oxygen levels in the blood that will cause damage to the lungs known as pulmonary embolism. The approach for diagnosing DVT has evolved over the years. Actually, anticoagulation therapy is used to treat DVT, whereas procedures including thrombolysis and placement of inferior vena cava filters are kept for a special situation.

Market Overview

An estimated 10 million population is affected by Thrombosis worldwide every year. Treatment includes thrombolytic and anticoagulants. The study of DVT treatment market includes Heparin, Apixaban, Dabigatran, Rivaroxaban, Edoxaban, Warfarin, Compression Therapy, Inferior Vena Cava Filter, and Thrombolytic Therapy. Anticoagulant therapy remains the important stay of medical therapy for deep venous thrombosis (DVT) because it is noninvasive; it treats most patients (approximately 90%) with no immediate demonstrable physical sequelae of DVT. While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants has provided clinicians with an expanding set of therapeutic options for DVT.

The FDA approved drugs include apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban (Xarelto), Savaysa (edoxaban), and betrixaban (Portola), which are alternatives to warfarin to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban, edoxaban, rivaroxaban, and betrixaban inhibit factor Xa, whereas dabigatran is a direct thrombin inhibitor. The clinical pipeline consists of more number of studies with most of the studies found under phase 3 stage of clinical trials compared to early phase, phase1, and phase 2 clinical trials. The drugs in phase 3 stage of clinical trial development include Tinzaparin by LEO Pharma/Novo Nordisk, Enoxaparin by Sanofi, Dalteparin by Pfizer, Heparin, Warfarin, acetylsalicylic acid, and others.

Globally, development of efficient and advanced technology, the rising awareness among people regarding present treatments for deep vein thrombosis, increase in government initiatives across the globe, growth in prevalence and incidence rate of deep vein thrombosis are the prime growth drivers of the DVT treatment market. Additionally, an increase in adoption of DVT treatment in emerging economies including China, India, and others, will create new opportunities for the DVT treatment market. However, the higher cost of the research and development, and complex government regulatory approvals are the key restraints for the DVT treatment market.

Key Developments

• In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor, and backup compounds.


• In Jan 2019, the first-in-human case using the new deep vein thrombosis (DVT) device Vetex thrombectomy catheter (Vetex Medical) has recently been completed human trial in a multicentre study. The device has the potential in reducing hospital stays and costs associated with DVT treatment.

Segmentation

It segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality (Heparin, Apixaban, Rivaroxaban, Edoxaban, Dabigatran, Warfarin,Inferior Vena Cava Filter, Thrombolytic Therapy, and  Compression Therapy), and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with close to 43% of the pipeline molecules administered through this mode.